MX2021000444A - Andamiaje de peptido de autoensamble. - Google Patents
Andamiaje de peptido de autoensamble.Info
- Publication number
- MX2021000444A MX2021000444A MX2021000444A MX2021000444A MX2021000444A MX 2021000444 A MX2021000444 A MX 2021000444A MX 2021000444 A MX2021000444 A MX 2021000444A MX 2021000444 A MX2021000444 A MX 2021000444A MX 2021000444 A MX2021000444 A MX 2021000444A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- self
- hapten
- peptide scaffold
- helices
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697132P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/041601 WO2020014609A2 (en) | 2018-07-12 | 2019-07-12 | Self-assembling peptide scaffold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000444A true MX2021000444A (es) | 2021-05-27 |
Family
ID=69142622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000444A MX2021000444A (es) | 2018-07-12 | 2019-07-12 | Andamiaje de peptido de autoensamble. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12458692B2 (https=) |
| EP (2) | EP4218928A3 (https=) |
| JP (2) | JP2021531337A (https=) |
| KR (1) | KR20210065086A (https=) |
| CN (1) | CN112512552B (https=) |
| AU (2) | AU2019300038C1 (https=) |
| BR (1) | BR112021000455A2 (https=) |
| CA (1) | CA3105706A1 (https=) |
| MA (1) | MA52591A (https=) |
| MX (1) | MX2021000444A (https=) |
| WO (1) | WO2020014609A2 (https=) |
| ZA (1) | ZA202100952B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7677953B2 (ja) * | 2019-09-12 | 2025-05-15 | ヘキサマー・セラピューティクス・インコーポレイテッド | 前立腺癌処置のための免疫治療薬 |
| US20230346920A1 (en) * | 2020-05-04 | 2023-11-02 | Hexamer Therapeutics, Inc. | Vaccines against viral pathogens |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432260A (en) * | 1991-05-03 | 1995-07-11 | Washington University | High affinity mannose receptor ligands |
| GB9202219D0 (en) | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| EP1237930B1 (en) | 1999-12-08 | 2006-11-08 | Intellect Neurosciences, Inc. | Chimeric amyloid beta peptides |
| US8575070B2 (en) | 2006-02-20 | 2013-11-05 | Phylogica Limited | Methods of constructing and screening libraries of peptide structures |
| WO2009030780A2 (en) * | 2007-09-07 | 2009-03-12 | Complix Nv | Non-natural proteinaceous scaffold made of three non-covalently associated peptides |
| WO2009134339A2 (en) * | 2008-04-29 | 2009-11-05 | Monsanto Technology, Llc | Genes and uses for plant enhancement |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| WO2013009971A1 (en) * | 2011-07-12 | 2013-01-17 | E. I. Du Pont De Nemours And Company | Detection and screening method and materials useful in performance thereof |
| WO2014126828A1 (en) * | 2013-02-15 | 2014-08-21 | Merck Sharp & Dohme Corp. | Novel ph-switchable peptides for membrane insertion and pore formation |
| CA2959201C (en) * | 2013-09-16 | 2021-06-01 | The University Of Queensland | Silica micro- and nano-capsules and methods for making them |
| WO2015164798A1 (en) | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| AU2016419048B2 (en) * | 2016-08-11 | 2024-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
-
2019
- 2019-07-12 MA MA052591A patent/MA52591A/fr unknown
- 2019-07-12 US US17/258,297 patent/US12458692B2/en active Active
- 2019-07-12 KR KR1020217003917A patent/KR20210065086A/ko active Pending
- 2019-07-12 CA CA3105706A patent/CA3105706A1/en active Pending
- 2019-07-12 EP EP23159271.8A patent/EP4218928A3/en active Pending
- 2019-07-12 MX MX2021000444A patent/MX2021000444A/es unknown
- 2019-07-12 JP JP2021523579A patent/JP2021531337A/ja active Pending
- 2019-07-12 WO PCT/US2019/041601 patent/WO2020014609A2/en not_active Ceased
- 2019-07-12 EP EP19834786.6A patent/EP3826661A4/en not_active Withdrawn
- 2019-07-12 CN CN201980046185.0A patent/CN112512552B/zh active Active
- 2019-07-12 BR BR112021000455-6A patent/BR112021000455A2/pt unknown
- 2019-07-12 AU AU2019300038A patent/AU2019300038C1/en active Active
-
2021
- 2021-02-11 ZA ZA2021/00952A patent/ZA202100952B/en unknown
-
2023
- 2023-04-11 AU AU2023202175A patent/AU2023202175A1/en active Pending
-
2024
- 2024-02-01 JP JP2024014081A patent/JP2024036461A/ja active Pending
-
2025
- 2025-10-27 US US19/370,520 patent/US20260061049A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021000455A2 (pt) | 2021-04-06 |
| AU2023202175A1 (en) | 2023-05-04 |
| CN112512552A (zh) | 2021-03-16 |
| WO2020014609A4 (en) | 2020-04-16 |
| US12458692B2 (en) | 2025-11-04 |
| CN112512552B (zh) | 2024-10-22 |
| EP3826661A4 (en) | 2022-08-31 |
| ZA202100952B (en) | 2023-10-25 |
| AU2019300038B2 (en) | 2023-01-12 |
| AU2019300038C1 (en) | 2024-01-04 |
| JP2021531337A (ja) | 2021-11-18 |
| US20260061049A1 (en) | 2026-03-05 |
| EP4218928A3 (en) | 2023-12-13 |
| CA3105706A1 (en) | 2020-01-16 |
| WO2020014609A3 (en) | 2020-02-20 |
| MA52591A (fr) | 2021-06-02 |
| EP4218928A2 (en) | 2023-08-02 |
| EP3826661A2 (en) | 2021-06-02 |
| JP2024036461A (ja) | 2024-03-15 |
| US20210268105A1 (en) | 2021-09-02 |
| WO2020014609A2 (en) | 2020-01-16 |
| KR20210065086A (ko) | 2021-06-03 |
| AU2019300038A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
| CY1124632T1 (el) | Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες | |
| PE20251185A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| CY1115413T1 (el) | Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation | |
| JP2019500327A5 (https=) | ||
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| PH12015502180B1 (en) | Wt1-antigen peptide conjugate vaccine | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| WO2019050362A3 (ko) | 인간 dlk1에 대한 항체 및 이의 용도 | |
| ZA202100952B (en) | Self-assembling peptide scaffold | |
| EA201892233A1 (ru) | Композиции и способы, связанные с иммуногенами вич-1 | |
| WO2006110831A3 (en) | Method of inducing neutralizing antibodies to human immunodeficiency virus | |
| EP2762153A3 (en) | Vaccine composition for mucosal administration | |
| WO2016005474A8 (en) | Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein | |
| EP2281574A4 (en) | ANTIGEN AND ARZNEE VEHICLE WITH A SYNTHETIC PEPTIDE AND THIS USE MUCOSAL VACCINE | |
| MX2018012504A (es) | Anticuerpos y antígenos de chagas, y composiciones, métodos y usos de los mismos. | |
| PE20220809A1 (es) | Anticuerpos anti-angpt2 | |
| EA200601030A1 (ru) | 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ | |
| PE20060860A1 (es) | Vacuna basada en epitopes neutralizantes | |
| ITUA20161610A1 (it) | Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso. |